Suppr超能文献

多发性骨髓瘤可能受稳态控制机制调节的证据:体外克隆性骨髓瘤细胞数量变化与临床反应的相关性。

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

作者信息

Maitland J A, Millar B C, Bell J B, Montes A, Treleaven J, Gore M E, McElwain T J

机构信息

Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.

出版信息

Br J Cancer. 1990 Mar;61(3):429-33. doi: 10.1038/bjc.1990.94.

Abstract

Myeloma colonies (MY-CFUc) could be grown in vitro for 6 months (median time) after a group of 12 myeloma patients had reached complete remission (CR). In a second group of 25 patients MY-CFUc increased in 17/25 and GM-CFUc in 20/25 patients after cyclophosphamide even though 24/25 patients had a partial response to VAMP and one was in CR. These data suggest that cell killing by cyclophosphamide stimulates residual tumour cells into proliferation and adds further support to the idea that myeloma is under some degree of homeostatic control which may be analogous to that in normal bone marrow. Although lymphoplasmacytoid myeloma cells may be more drug resistant than plasmacytoid myeloma cells in vitro, it was not possible to conclude that the emergence of lymphoplasmacytoid cells at relapse was indicative of resistance to further treatment.

摘要

在一组12例骨髓瘤患者达到完全缓解(CR)后,骨髓瘤集落(MY-CFUc)能够在体外培养6个月(中位时间)。在第二组25例患者中,尽管24/25例患者对VAMP有部分反应且1例处于CR,但环磷酰胺治疗后17/25例患者的MY-CFUc增加,20/25例患者的GM-CFUc增加。这些数据表明,环磷酰胺导致的细胞杀伤刺激残留肿瘤细胞增殖,并进一步支持了骨髓瘤处于某种程度的稳态控制之下这一观点,这种稳态控制可能类似于正常骨髓中的情况。虽然在体外淋巴浆细胞样骨髓瘤细胞可能比浆细胞样骨髓瘤细胞更具耐药性,但无法得出复发时淋巴浆细胞样细胞的出现表明对进一步治疗耐药的结论。

相似文献

本文引用的文献

6
A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro.
Br J Haematol. 1988 Jun;69(2):197-203. doi: 10.1111/j.1365-2141.1988.tb07622.x.
7
Idiotypes and anti-idiotypes in myeloma.骨髓瘤中的独特型与抗独特型
Hematol Oncol. 1988 Apr-Jun;6(2):103-6. doi: 10.1002/hon.2900060208.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验